1、Achieving CAR T-cell Therapy Health System Readiness AN ASSESSMENT OF BARRIERS AND OPPORTUNITIESMARCH202 5CAR T-cell therapies have shown substantial efficacy in several hematological conditions and hold the potential for transformative benefits in other difficult to treat diseases;however,the compl

2、ex journey to deliver CAR T-cell therapies to patients and associated operational and capacity needs can lead to suboptimal access to and use of these therapies.Despite these therapies first launching globally in 2017,barriers to patient access remain.In this report,the current health system capacit

3、y for delivering CAR T-cell therapies to patients was assessed in seven countries(Australia,Canada,France,Germany,Italy,Spain,the United Kingdom).This includes reimbursement and funding,patient referral,treatment,and long-term follow-up.This report provides background on the complex CAR T-cell thera

4、py patient journey from patient identification and referral to long-term monitoring,and estimates CAR T-cell therapy utilization in a subset of countries.The current state of health system readiness is assessed in detail for each of the seven countries,including national or regional strategies,patie

5、nt identification and referral,and treatment initiation,administration,and monitoring.Key barriers and best practices for enhancing the delivery of CAR T-cell therapies are also highlighted for each country.Based on this assessment and learning from best practices,potential solutions are provided to

6、 improve patient access to CAR T-cell therapies.This report is intended to provide a foundation for discussions around key barriers and actions or policies that could be tailored to specific country or regional needs to ensure the full potential of CAR T-cell therapies is realized.The study was prod